mProX™ Human CLDN18 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CLDN18 Stable Cell Line (S01YF-1023-PY261). Click the button above to contact us or submit your feedback about this product.
Cameron Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Jordan Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Expression of claudin-18 abrogates miR-1303 promoting migration function.
After transfection with miR-1303 mimics, a decrease in Claudin-18 levels was observed in BGC-823 cells, and conversely, an increase in Claudin-18 levels was observed after transfection with the miR-1303 inhibitor. Nevertheless, when miR-1303 mimics were co-transfected with the CLDN18 vector lacking 3'UTR (pcDNA3.1-claudin), Claudin-18 expression was significantly increased, effectively nullifying the inhibitory impact of miR-1303 mimics on Claudin-18 expression.
Ref: Zhang, Shi-jie, et al. "miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells." Digestive diseases and sciences 59 (2014): 1754-1763.
Pubmed: 24647998
DOI: 10.1007/s10620-014-3107-5
Research Highlights
Coy, Shannon. et al. "Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors." Neuro-oncology, 2023.
Antibody-drug conjugates (ADCs) have been shown to increase the specificity of cytotoxic drugs by directing them to cells expressing target antigens. FDA-approved ADCs have been used to treat both solid and hematologic malignancies, specifically those expressing HER2, TROP2, and NECTIN4. In recent studies, a specific ADC targeting HER2 (Trastuzumab-Deruxtecan) has exhibited promising results in increasing survival rates and reducing growth of brain metastases in treatment-refractory metastatic breast cancer, even in tumors with low HER2 expression. This suggests that even low levels of expression of ADC targets may elicit a positive treatment response. Nevertheless, the characterization of ADC target expression in central nervous system (CNS) tumors remains inadequate.
Coy, Shannon. et al. "Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors." Neuro-oncology, 2023.
Pubmed:
37870091
DOI:
10.1093/neuonc/noad205
Bähr-Mahmud, Hayat. et al. "Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody." Oncoimmunology, 2023.
IMAB362/Zolbetuximab, a first-in-class IgG1 antibody targeting the cancer-associated gastric-lineage marker CLDN18.2, has shown promising results in two phase 3 trials as a first-line treatment in combination with standard chemotherapy for CLDN18.2-positive Her2 negative advanced gastric cancer. The pharmacology of a potential RNA therapeutic, BNT141, which encodes the sequence of IMAB362/Zolbetuximab and is formulated in lipid nanoparticles (LNP) for liver uptake, has been characterized. Preclinical studies demonstrate the stable pharmacokinetic profile of the mRNA-encoded antibody, as well as its ability to mediate CLDN18.2-restricted cytotoxicity and inhibit tumor growth in animal models. These findings support the initiation of a phase 1/2 clinical trial (NCT04683939) for advanced CLDN18.2-expressing solid cancers using BNT141 mRNA-LNP.
Bähr-Mahmud, Hayat. et al. "Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody." Oncoimmunology, 2023.
Pubmed:
37860278
DOI:
10.1080/2162402X.2023.2255041
